Clinical Trial Update: Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer [Phase 3]

View source ↗

Summary

A Phase III randomized trial is evaluating Fluzoparib in combination with Apatinib versus investigator-selected chemotherapy for HRD-positive/HER2-negative adva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Apatinib (apatinib)
• Fluzoparib (fluzoparib)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer | Phase 3 | Status: RECRUITING